# Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

> **NCT05890118** · PHASE1 · COMPLETED · sponsor: **RANI Therapeutics** · enrollment: 55 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Stelara
- **COMBINATION_PRODUCT:** RT-111 (0.5mg)
- **COMBINATION_PRODUCT:** RT-111 (0.75mg)

## Key facts

- **NCT ID:** NCT05890118
- **Lead sponsor:** RANI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-30
- **Primary completion:** 2023-11-28
- **Final completion:** 2023-11-28
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05890118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05890118, "Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05890118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*